Novartis’ Kymriah okayed for funding in Scotland for lymphomaNovartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness Share XNovartis’ Kymriah okayed for funding in Scotland for lymphomahttps://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/
Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
NHS funds eye gene therapy, after Novartis cuts £613,000 priceNICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed Share XNHS funds eye gene therapy, after Novartis cuts £613,000 pricehttps://pharmaphorum.com/news/nhs-funds-eye-gene-therapy-after-novartis-cuts-613000-price/
Mylan’s Lantus biosimilar held up by manufacturing issueMylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient Share XMylan’s Lantus biosimilar held up by manufacturing issuehttps://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarNovartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar Share XNovartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarhttps://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/
Mylan up on OK for generic of Lilly’s $2bn cancer drug AlimtaShares in Mylan have risen after the FDA gave a tentative approval to its generic version of Eli Share XMylan up on OK for generic of Lilly’s $2bn cancer drug Alimtahttps://pharmaphorum.com/news/mylan-up-on-ok-for-generic-of-lillys-2bn-cancer-drug-alimta/
GW confident epilepsy drug will get NHS funding despite NICE rejectionThe UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis Share XGW confident epilepsy drug will get NHS funding despite NICE rejectionhttps://pharmaphorum.com/news/no-repeat-of/
AZ buys cut price priority review voucher, but for what?AstraZeneca has bought a priority review voucher (PRV) from Swedish biotech Sobi for $95 million, but isn’t revealing Share XAZ buys cut price priority review voucher, but for what?https://pharmaphorum.com/news/az-buys-cut-price-priority-review-voucher-but-for-what/
After two decades taking on pharma over price, Sir Andrew Dillon steps down from NICEAfter more than 20 years of challenging pharma over drug prices, Sir Andrew Dillon is to step down Share XAfter two decades taking on pharma over price, Sir Andrew Dillon steps down from NICEhttps://pharmaphorum.com/news/after-two-decades-taking-on-pharma-over-price-sir-andrew-dillon-steps-down-from-nice/
